Mckesson lifts annual profit forecast on robust demand for specialty drugs

Drug distributor McKesson (MCK.N) raised its fiscal 2026 profit forecast to $37.10-$37.90 per share and surpassed first-quarter revenue and earnings estimates. The company reported Q1 revenue of $97.83 billion and adjusted EPS of $8.26, exceeding analyst expectations. This strong performance was primarily driven by robust demand for high-margin specialty drugs and increased prescription volumes, highlighting the growing profitability within the specialty medicine market, a trend also observed with peer Cencora.

Analysis

McKesson (MCK) has demonstrated significant operational strength by raising its fiscal 2026 profit forecast and delivering first-quarter results that surpassed Wall Street estimates. The company now projects an EPS range of $37.10 to $37.90, an upward revision that favorably brackets the analyst consensus of $37.41. This improved outlook is supported by a robust first quarter, where revenue hit $97.83 billion against a $96.08 billion estimate, and adjusted EPS reached $8.26, beating the expected $8.15. The core drivers of this outperformance are strong demand for high-margin specialty drugs and higher prescription volumes. This is clearly reflected in its largest segment, U.S. Pharmaceutical, which posted a 25% year-over-year revenue increase to $89.95 billion. The positive trend is not isolated to McKesson, as peer Cencora (COR) also raised its forecast, indicating favorable sector-wide dynamics. Furthermore, McKesson's strategic decision to spin off its medical-surgical unit sharpens its focus on this high-performing core drug distribution business, potentially enhancing future value creation.

Key Decisions for Investors

• Given the strong earnings beat and upwardly revised annual guidance driven by its high-margin specialty drug segment, investors could interpret this as a bullish signal for McKesson's near-term performance.
• The parallel positive guidance from peer Cencora suggests a broad industry tailwind, warranting a review of investment exposure across the drug distribution sector, not just McKesson in isolation.
• Investors should monitor the execution and financial impact of the planned spin-off of the medical-surgical unit, as it is intended to unlock value by concentrating resources on the core pharmaceutical business.
• Sustained growth in specialty product distribution and overall prescription volumes are critical to the investment thesis, making these key performance indicators to watch in subsequent quarters.